We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+29.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.47B
AUM Growth
+$451M
Cap. Flow
+$1.13B
Cap. Flow %
11.96%
Top 10 Hldgs %
21.59%
Holding
903
New
107
Increased
255
Reduced
393
Closed
103

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$51.9M
2
MRK icon
Merck
MRK
+$50.9M
3
DHR icon
Danaher
DHR
+$45.3M
4
TMO icon
Thermo Fisher Scientific
TMO
+$37.8M
5
JD icon
JD.com
JD
+$37.7M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$103M
2
BABA icon
Alibaba
BABA
+$98.6M
3
CRM icon
Salesforce
CRM
+$62.5M
4
BMY icon
Bristol-Myers Squibb
BMY
+$59.4M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$48.6M

Sector Composition

Rank Sector Weight
1 Healthcare 34.61%
2 Technology 20.94%
3 Consumer Discretionary 8.9%
4 Financials 8.59%
5 Communication Services 7.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MSFT icon
1
Microsoft
MSFT
$2.9T
$435M 4.59%
2,136,255
-36,725
-2% -$6.67M
AAPL icon
2
Apple
AAPL
$4.77T
$231M 2.43%
2,527,744
-213,140
-8% -$16.5M
GOOGL icon
3
Alphabet (Google) Class A
GOOGL
$4.25T
$225M 2.38%
3,179,720
-4,300
-0.1% -$290K
AMZN icon
4
Amazon
AMZN
$2.62T
$223M 2.35%
1,616,020
+4,980
+0.3% +$601K
AMGN icon
5
Amgen
AMGN
$198B
$206M 2.17%
871,290
-33,678
-4% -$7.68M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$121B
$159M 1.67%
546,191
-179,170
-25% -$48.6M
MRK icon
7
Merck
MRK
$317B
$158M 1.66%
2,136,419
+675,881
+46% +$50.9M
REGN icon
8
Regeneron Pharmaceuticals
REGN
$70B
$143M 1.51%
228,901
-182,315
-44% -$103M
META icon
9
Meta Platforms (Facebook)
META
$1.6T
$137M 1.45%
605,114
+44,998
+8% +$9.39M
GILD icon
10
Gilead Sciences
GILD
$163B
$130M 1.37%
1,690,025
-566,972
-25% -$43.5M
PYPL icon
11
PayPal
PYPL
$49.1B
$108M 1.14%
619,403
+112,440
+22% +$15.5M
DHR icon
12
Danaher
DHR
$124B
$105M 1.11%
670,352
+315,975
+89% +$45.3M
PG icon
13
Procter & Gamble
PG
$348B
$103M 1.08%
859,359
-92,927
-10% -$10.8M
TMO icon
14
Thermo Fisher Scientific
TMO
$193B
$96.5M 1.02%
266,341
+112,713
+73% +$37.8M
BIIB icon
15
Biogen
BIIB
$29.6B
$91.2M 0.96%
340,919
-53,346
-14% -$16M
BMY icon
16
Bristol-Myers Squibb
BMY
$125B
$88.5M 0.93%
1,505,038
-993,760
-40% -$59.4M
V icon
17
Visa
V
$676B
$73.2M 0.77%
379,065
-5,898
-2% -$1.08M
BABA icon
18
Alibaba
BABA
$278B
$71.2M 0.75%
329,846
-473,323
-59% -$98.6M
ADSK icon
19
Autodesk
ADSK
$43.3B
$71.1M 0.75%
297,114
+7,358
+3% +$1.45M
BPMC
20
DELISTED
Blueprint Medicines
BPMC
$68.5M 0.72%
878,644
+767,413
+690% +$51.9M
ILMN icon
21
Illumina
ILMN
$29.2B
$68M 0.72%
188,677
-40,605
-18% -$13.1M
SGEN
22
DELISTED
Seagen Inc. Common Stock
SGEN
$66.4M 0.7%
390,919
+10,991
+3% +$1.64M
DIS icon
23
Walt Disney
DIS
$168B
$65.5M 0.69%
587,783
-43,912
-7% -$4.85M
ABBV icon
24
AbbVie
ABBV
$453B
$65.2M 0.69%
663,570
-78,451
-11% -$6.91M
GOOG icon
25
Alphabet (Google) Class C
GOOG
$4.24T
$64.8M 0.68%
916,180
+168,140
+22% +$11.3M
1
2 3 4 5

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q2 2020 Portfolio in Review

As of Q2 2020, Candriam SCA held 903 positions worth $9.47B, up 5% from $9.02B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Candriam SCA deployed $1.13B of net new capital in Q2 2020, opening 107 new positions and adding to 255 existing holdings. Its largest new stake was JD.com: 744,410 shares worth $44.8M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 31% a quarter earlier, followed by Technology and Consumer Discretionary.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $103M trimmed.

  • Candriam SCA's largest Q2 2020 buy was JD.com: 744,410 shares worth $44.8M.
  • Candriam SCA added most to Blueprint Medicines in Q2 2020, an estimated $51.9M increase.
  • Candriam SCA's biggest Q2 2020 reduction was Regeneron Pharmaceuticals, cutting an estimated $103M.
  • Candriam SCA fully exited Salesforce in Q2 2020, selling an estimated $62.5M.
  • Candriam SCA's ten largest holdings make up 22% of its $9.47B portfolio in Q2 2020.
  • Candriam SCA opened 107 new positions and closed 103 in Q2 2020.
  • Candriam SCA's portfolio value rose 5% quarter-over-quarter to $9.47B.

Based on Candriam SCA's 13F filing for Q2 2020, filed 23 Jul 2020.